Optimization of Intensive Care for Nephro- and Hepatotoxicity of Lung Cancer Chemotherapy

Authors

  • Nuriddin Hamzaevich Ergashev Tashkent State Medical University, Uzbekistan Author
  • Zoir Takhirovich Gaziev Tashkent State Medical University, Uzbekistan Author
  • Kamola Ravshanovna Umarova Tashkent State Medical University, Uzbekistan Author

Keywords:

Lung cancer, chemotherapy, nephrotoxicity, hepatotoxicity

Abstract

Lung cancer remains the leading cause of cancer mortality worldwide, and systemic chemotherapy is a cornerstone of treatment for advanced stages. However, many chemotherapeutic agents used in lung cancer can cause significant nephrotoxicity and hepatotoxicity, which may limit therapy, necessitate dose reductions, or even lead to life-threatening organ failure. Cisplatin-based regimens, for example, are highly effective but carry a well-documented risk of acute kidney injury (AKI) due to proximal tubular damage, electrolyte disturbances, and reduced glomerular filtration. Likewise, various cytotoxic drugs can induce liver injury in idiosyncratic patterns ranging from transient asymptomatic transaminase elevations to fulminant hepatic failure. Optimizing intensive care management of these toxicities is essential to ensure patients can safely continue potentially curative treatments. This narrative review summarizes the nephrotoxic and hepatotoxic effects of common lung cancer chemotherapeutic agents and discusses strategies to prevent and mitigate these toxicities.

Tibbiyot muqovasi

Downloads

Index links

Google Scholar Zenodo OpenAIRE BASE OpenAlex Semantic Scholar DataCite

Published

2026-11-11

Issue

No. 11 (2026): November 2026

Section

Articles

How to Cite

Optimization of Intensive Care for Nephro- and Hepatotoxicity of Lung Cancer Chemotherapy. (2026). Tibbiyot, 11, 44-52. https://reandpub.uz/tibbiyot/article/view/1525

References

World Health Organization. Lung cancer: Fact sheet. (26 June 2023). – Available at: who.int (accessed 26 Nov 2025).

Lyrio R. M. da C., Rocha B. R. A., Corrêa A. L. R. M., et al. Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches // Frontiers in Nephrology. – 2024. – Vol.4. – P. 275-284. frontiersin.orgfrontiersin.org.

Mudd T. W., Guddati A. K. Management of hepatotoxicity of chemotherapy and targeted agents // American Journal of Cancer Research. – 2021. – 11(7). – P. 3461–3474. researchgate.netresearchgate.net.

Podręcznik BCCancer. Cisplatin Monograph. – BC Cancer Agency, 2019. – P. 110-118. bccancer.bc.cabccancer.bc.ca.

Totri J., Silver E., Gilbar P. Hydration methods for cisplatin chemotherapy // Asia-Pacific Journal of Clinical Oncology. – 2019. – 15(5). – P. 391-397. dam.esmo.orgesmoopen.com.

Arany I., Safirstein R. L. Cisplatin nephrotoxicity // Seminars in Nephrology. – 2003. – 23(5). – P. 460-464. e-century.use-century.us.

Izzedine H., Launay-Vacher V., Deray G. Anticancer drug-induced glomerular toxicity: a review // Nephrology Dialysis Transplantation. – 2005. – 20(4). – P. 848-855. e-century.use-century.us.

Jhaveri K. D., Palomba M. L., Shah H. H., et al. Onco-Nephrology: the Latest Frontier in the War against Cancer // Journal of Clinical Oncology. – 2014. – 32(21). – P. 2384-2389. e-century.use-century.us.

Thatishetty A. V., Agresti N., O’Brien C. B. Chemotherapy-induced hepatotoxicity // Clinics in Liver Disease. – 2013. – 17(4). – P. 671-686. pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov.